New shot could tame stubborn hives when pills fail
NCT ID NCT07402213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main goal is to see if the drug reduces hive activity and itching scores after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JYB1904 injection
What this could lead to
If it works, this could provide a new treatment option for people with chronic hives that don't respond well to standard antihistamines.
What could go wrong
This is an early Phase 3 trial with only 180 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••